ML365 is a selective inhibitor of the enzyme FTO (fat mass and obesity-associated protein), which plays a role in RNA demethylation. By targeting FTO, ML365 is used in research to study the epigenetic regulation of gene expression, particularly involving N6-methyladenosine (m6A) modifications in mRNA. This compound helps investigate the link between RNA methylation and various biological processes, including cell differentiation, metabolism, and cancer progression. It has been applied in studies exploring potential therapeutic strategies for cancers where FTO is overexpressed, such as acute myeloid leukemia, by promoting the accumulation of m6A marks and altering oncogene expression. Additionally, ML365 serves as a tool compound for validating FTO as a drug target in metabolic and neurological disorders.